Pfizer CEO Says No Big Deals for Now -- WSJ

By Lizzy Lawrence

Pfizer, historically one of the biggest dealmakers in pharma, is out of the game**-**for now.

CEO Albert Bourla said the company is instead focusing on the cancer and obesity drugs it acquired through the $43 billion deal for Seagen and the $10 billion buyout of Metsera.

"It's not what is ahead of us," Bourla said when asked about future deals in an interview Tuesday after the company's third quarter earnings call. "It is what is ahead of the investments that we have done already."

Recent dealmaking hasn't left a lot of money for Pfizer to spend. Chief Financial Officer Cecile Guegan said the company has around $6 billion for mergers and acquisitions and may pursue smaller deals.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

November 03, 2026 14:28 ET (19:28 GMT)